Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.
JNCI Cancer Spectr
; 8(4)2024 Jul 01.
Article
en En
| MEDLINE
| ID: mdl-39115391
ABSTRACT
High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608â100 (interquartile range, IQR = $534â100-$732â800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402â500, and the median out-of-pocket copayment was $510. Monthly costs were highest during the month of CAR-T therapy administration (median = $521â500), with median costs below $25â000 in all other 28-day intervals. Costs of CAR-T therapy use were substantial, largely driven by product acquisition. Future studies should examine the relationship between costs, access, and financial outcomes.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inmunoterapia Adoptiva
/
Linfoma de Células B Grandes Difuso
/
Receptores Quiméricos de Antígenos
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
JNCI Cancer Spectr
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos